Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Japanese pharmaceutical company Kissei Pharmaceutical Co and Eisai have signed a licensing agreement for Urief, a treatment for dysuria associated with benign prostatic hyperplasia originally discovered and developed by Kissei.
Subscribe to our email newsletter
With this agreement, Eisai obtained the exclusive rights for development and marketing of Urief in 10 ASEAN (Association of South East Asian Nations) countries, as well as India and Sri Lanka.
Kissei has been actively promoting international deployment through out-licensing activities of its original products. This licensing agreement for Urief with Eisai for new territories will enable Kissei to contribute to the improvement of quality of life for more people with urination difficulties.
Eisai is reported to be increasing its presence in the ASEAN countries and India with its global products including Aricept, the treatment of Alzheimer’s disease, and Pariet, a proton pump inhibitor.
In 2007, both companies signed a licensing agreement and Eisai obtained the exclusive rights for development and marketing of Glufast, a rapid acting insulin secretagogue originally discovered and developed by Kissei, in 10 ASEAN countries and China. The compound has been filed by Eisai for approval in Indonesia, Malaysia, the Philippines, Singapore, and Thailand.